Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves

Cardiovascular Therapeutics

Volumn 33, Issue 6, 2015, Pages 324-328

  An, Sook Hee ^a   Chang, Byung Chul ^b   Lee, Kyung Eun ^c,d   Gwak, Hye Sun ^c  

^a Wonkwang University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Ewha Womans University   (South Korea)

^d Chungbuk National University   (South Korea)

Author keywords

Cytochrome P450 subfamily 2C polypeptide 9 (CYP2C9); Polymorphism; Uridine diphosphate (UDP) Glucuronosyltransferase (UGT); Warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; DNA; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450 FAMILY 4; UGT1A1 ENZYME; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEART VALVE REPLACEMENT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; WILD TYPE; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING; DEVICES; DRUG EFFECTS; DRUG MONITORING; GENE FREQUENCY; GENETICS; HEART VALVE PROSTHESIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROCEDURES; SOUTH KOREA; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROME P450 FAMILY 4; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REPUBLIC OF KOREA; THROMBOSIS; TREATMENT OUTCOME; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84945972618     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12147     Document Type: Article

References (22)

1. Glurich I, Burmester JK, Caldwell MD. Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev 2010;15:239-248.
2. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-2303.
3. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008;9:511-526.
4. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004;91:87-94.
5. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: A prospective study. J Thromb Thrombolysis 2006;22:191-197.
6. Caldwell MD, Awad T, Johnson JA, et al. Cyp4F2 genetic variant alters required warfarin dose. Blood 2008;111:4106-4112.
7. Borgiani P, Ciccacci C, Forte V, et al. Cyp4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009;10:261-266.
8. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney-role of cyp4f2 and cyp4a11. J Biol Chem 2000;275:4118-4126.
9. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625-629.
10. Liang R, Li L, Li C, et al. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis 2012;34:120-125.
11. Miller GP, Jones DR, Sullivan SZ, et al. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol 2009;22:1239-1245.
12. Zielinska A, Lichti CF, Bratton S, et al. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 2008;324:139-148.
13. Jones DR, Moran JP, Miller GP. Warfarin and UDP-glucuronosyltransferases: Writing a new chapter of metabolism. Drug Metab Rev 2010;42:55-61.
14. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:E576S-E600S.
15. Sun XA, Hu SS, Qi GQ, Zhou YY. Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves. Chin Med J 2003;116:1175-1178.
16. Matsuyama K, Matsumoto M, Sugita T, et al. Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J 2002;66:668-670.
17. Yoon IK, Lee KE, Lee JK, Chang BC, Gwak HS. Adequate intensity of warfarin therapy for Korean patients with mechanical cardiac valves. J Heart Valve Dis 2013;22:102-109.
18. Zhou Y, Wang SN, Li H, et al. Association of UGT1A1 variants and hyperbilirubinemia in breast-fed full-term Chinese infants. PLoS One 2014;9:e104251.
19. Zhou Y, Wang SN, Li H, et al. Quantitative trait analysis of polymorphisms in two bilirubin metabolism enzymes to physiologic bilirubin levels in Chinese newborns. J Pediatr 2014;165:1154-1160.
20. de Oliveira Almeida VC, Ribeiro DD, Gomes KB, Godard AL. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: A prospective cohort study. Mol Diagn Ther 2014;18:675-683.
21. Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol 2010;23:939-945.
22. http://www.ncbi.nlm.nih.gov/snp.